Hikma given shot in the arm by ‘excellent’ double-digit growth Business Pharmaceutical firm Hikma has hiked its dividend and raised its guidance having hailed an “excellent” first half of the year. The Jordanian-founded FTSE 100 pharma firm, which in June bolstered its injectables offering with the purchase of Danish rival Xellia, posted a double-digit revenue rise of 10 per cent, raking in $1.6bn (£1.3bn) in the [...]
Hikma bolsters US injectables offering with purchase of Danish competitor pharma Hikma Pharmaceuticals has bolstered its US injectables capabilities with the purchase of several divisions of Danish competitor Xellia Pharmaceuticals.
Hikma: Pharma giant starts year strong as new product sales surge in key markets pharma In 2023, the group became the second-largest pharmaceutical company in Middle East and North Africa by sales.